EP. 4: EyeCon 2022: Mindset to explore new opportunities for your practice
October 21st 2022An interactive agenda at the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will foster an open exchange of ideas with fellow attendees from across the United States.
Read More
How to express your passion through innovation: pearls for young ophthalmologists
October 10th 2022Murtaza Adam, MD, a vitreoretinal specialist with Colorado Retina Associates, shares a few principles he has found helpful when engaging with industry or trying to execute on your own innovation.
Read More
EP. 3: EyeCon 2022: High-impact content in a small-scale setting
October 6th 2022The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.
Read More
EyePoint Pharmaceuticals announces first patient dosed in Phase 2 DAVIO 2 clinical trial
August 3rd 2022According to the company, the clinical trial is reviewing EYP-1901, an investigational sustained delivery anti-vascular endothelial growth factor (anti-VEGF) treatment for wet age-related macular degeneration (wet AMD).
Read More
Akari Therapeutics announces positive results from recent pre-clinical studies
July 28th 2022Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatments.
Read More
How to inhibit photoreceptor death? A new way to fight pigmentary retinopathy
July 21st 2022A team of scientists, led by Andrzej Foik, PhD, of the International Center for Translational Eye Research in Poland, is working on new therapies that may slow vision loss in patients diagnosed with retinal degeneration.
Read More
ASRS LIVE: TRUCKEE Study shows real-world safety and efficacy of faricimab for neovascular AMD
July 16th 2022Speaking at the American Society of Retina Specialists 2022 annual meeting in New York, Carl Danzig, MD, detailed how treatment with faricimab in patients with neovascular AMD resulted in improvements in visual acuity, central subfield thickness and pigment epithelial detachments.
Read More
Two-year data confirms faricimab improves vision for patients diagnosed with wet-AMD
July 14th 2022In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.
Read More